Poly Medicure

Why is Poly Medicure Ltd falling/rising?

As of 15-Jun, Poly Medicure Ltd's stock is experiencing a decline of 1.22% after a trend reversal, with significant volatility during the trading day. The stock has underperformed long-term, with a year-to-date drop of 14.83% and a 32.33% decline over the past year, attributed to poor financial results and decreased investor interest.

As of 15-Jun, Poly Medicure Ltd's stock price is currently falling, with a change of -18.7, representing a decrease of 1.22%. This decline follows a trend reversal after two consecutive days of gains. Although the stock opened with a gain of 2.86% today and reached an intraday high of Rs 1575, it also touched a low of Rs 1498, indicating significant volatility within the trading day.<BR><BR>The stock has underperformed in the long term, with a year-to-date decline of 14.83% compared to a 10.51% drop in the benchmark index. Over the past year, the stock has fallen by 32.33%, significantly more than the market's negative return of 5.98%. This poor performance is attributed to several negative factors, including a decrease in profit after tax by 27.8% in the most recent quarter and a low return on capital employed at 13.08%. Additionally, the stock's valuation appears expensive with a price-to-book value of 4.9, despite being net-debt free and having high institutional holdings.<BR><BR>Furthermore, there has been a notable decline in investor participation, with delivery volume dropping by 50.23% against the 5-day average. This lack of interest from investors, combined with the company's disappointing financial results and poor long-term growth prospects, contributes to the stock's current downward trajectory.

Which are the latest news on Poly Medicure?

How big is Poly Medicure?

As of 10th June, Poly Medicure Ltd has a market capitalization of 14,595.00 Cr, with net sales of 1,875.26 Cr and a net profit of 322.14 Cr for the latest four quarters. The company reported shareholder's funds of 2,765.66 Cr and total assets of 3,192.13 Cr for the annual period ending March 2025.

As of 10th June, Poly Medicure Ltd has a market capitalization of 14,595.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Poly Medicure reported net sales of 1,875.26 Cr and a net profit of 322.14 Cr.<BR><BR>For the latest annual period ending March 2025, the company had shareholder's funds amounting to 2,765.66 Cr and total assets of 3,192.13 Cr.

Who are in the management team of Poly Medicure?

The management team of Poly Medicure includes key individuals such as Devendra Raj Mehta (Chairman), Himanshu Baid (Managing Director & CEO), and several non-executive directors, bringing diverse expertise to the company.

The management team of Poly Medicure includes the following key individuals:<BR><BR>1. **Devendra Raj Mehta** - Chairman & Independent Director<BR>2. **Jugal Kishore Baid** - Non-Executive & Non-Independent Director<BR>3. **Prakash Chand Surana** - Non-Executive & Independent Director<BR>4. **Himanshu Baid** - Managing Director & CEO<BR>5. **Rishi Baid** - Joint Managing Director<BR>6. **Shailendra Raj Mehta** - Non-Executive & Independent Director<BR>7. **Mukulika Baid** - Non-Executive & Non-Independent Director<BR>8. **Avinash Chandra** - Company Secretary & Compliance Officer<BR>9. **Sandeep Bhargava** - Non-Executive & Independent Director<BR>10. **Alessandro Balboni** - Non-Executive & Non-Independent Director<BR>11. **Amit Khosla** - Non-Executive & Independent Director<BR>12. **Sonal Matto** - Non-Executive & Independent Director<BR>13. **Ambrish Mithal** - Independent Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Who are the peers of the Poly Medicure?

Poly Medicure's peers include Dr Lal Pathlabs, Syngene Intl., Vijaya Diagnost., Indegene, Metropolis Health, Thyrocare Tech., Suven Life Sciences, Vimta Labs, and Krsnaa Diagnost. Most peers show below-average growth, with varying management risks and capital structures; Thyrocare Tech. leads in 1-year returns at 62.29%, while Poly Medicure has a return of -36.89%.

Peers: The peers of Poly Medicure are Dr Lal Pathlabs, Syngene Intl., Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, and Krsnaa Diagnost.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, Syngene Intl., and Metropolis Healt, while Good management risk is found at Poly Medicure, Vijaya Diagnost., Thyrocare Tech., and Indegene. Average management risk is noted at Vimta Labs and Krsnaa Diagnost., and Below Average management risk is present at Suven Life Scie. All peers exhibit Below Average growth, with the exception of Vijaya Diagnost., Metropolis Healt, and Thyrocare Tech., which have Good growth, while Indegene, Suven Life Scie., and Krsnaa Diagnost. show Average growth. Excellent capital structure is seen in Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Krsnaa Diagnost., while Average capital structure is noted at Indegene and Vimta Labs, and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Thyrocare Tech. at 62.29%, while the lowest is Syngene Intl. at -31.20%. Poly Medicure's 1-year return is -36.89%, which is lower than both. Additionally, Indegene, Suven Life Scie., and Krsnaa Diagnost. have negative six-month returns.

What does Poly Medicure do?

Poly Medicure Ltd is a small-cap manufacturer of medical devices, incorporated in 1995, with recent net sales of 535 Cr and a net profit of 66 Cr as of March 2026. The company has a market cap of INR 14,595 Cr and key financial metrics include a P/E ratio of 44.00 and a dividend yield of 0.24%.

Overview: <BR>Poly Medicure Ltd is a manufacturer of medical devices operating in the healthcare services industry within the small-cap market segment.<BR><BR>History: <BR>Poly Medicure Limited was incorporated on March 30, 1995. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 535 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 66 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 14,595 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 44.00 <BR>Industry P/E: 92 <BR>Dividend Yield: 0.24% <BR>Debt-Equity: -0.15 <BR>Return on Equity: 10.53% <BR>Price to Book: 4.76<BR><BR>Contact Details: <BR>Address: Property No 232B 3rd Floor, Okhla Indl Estate Phase-III New Delhi New Delhi : 110020 <BR>Tel: 91-11-26321838/81/89/93 <BR>Email: investorcare@polymedicure.com <BR>Website: http://www.polymedicure.com

Should I buy, sell or hold Poly Medicure Ltd?

Are Poly Medicure Ltd latest results good or bad?

Poly Medicure Ltd's latest results for Q4 FY26 show strong revenue growth of 21.25% to ₹534.51 crores, but a concerning 27.81% decline in net profit to ₹66.29 crores and deteriorating operating margins indicate significant challenges in cost management and profitability. Overall, the results are more negative than positive, highlighting urgent operational issues.

Poly Medicure Ltd's latest results for Q4 FY26 present a mixed picture, with significant concerns overshadowing the positive aspects. On one hand, the company achieved a notable revenue growth of 21.25% year-on-year, reaching ₹534.51 crores, which marks the highest quarterly revenue in its history. However, this impressive top-line performance is marred by a substantial decline in net profit, which fell by 27.81% year-on-year to ₹66.29 crores.<BR><BR>The operating margins also deteriorated, dropping to 20.65%, the lowest level in eight quarters, down from 27.10% in the same quarter last year. This indicates that while the company is generating more sales, it is struggling to convert those sales into profits effectively. Additionally, the profit after tax (PAT) margin decreased significantly from 20.83% to 12.17%, reflecting operational inefficiencies and rising costs, particularly in employee expenses, which surged by nearly 60% year-on-year.<BR><BR>Overall, the results suggest that Poly Medicure is facing critical challenges in managing costs and maintaining profitability despite strong revenue growth. This combination of declining profits and shrinking margins raises concerns about the company's operational efficiency and future performance. Therefore, the latest results can be viewed as more negative than positive, highlighting the need for management to address these issues urgently.

When is the next results date for Poly Medicure Ltd?

The next results date for Poly Medicure Ltd is 25 May 2026.

The next results date for Poly Medicure Ltd is scheduled for 25 May 2026.

Is Poly Medicure technically bullish or bearish?

As of November 10, 2025, Poly Medicure's technical trend is bearish with moderate strength, supported by daily moving averages and Bollinger Bands, despite mixed signals from the MACD across different time frames.

As of 10 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Poly Medicure is bearish with moderate strength. Key indicators driving this stance include the daily moving averages indicating a bearish trend, and both the weekly and monthly Bollinger Bands also confirming bearish conditions. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly, indicating mixed signals across time frames. Additionally, the Dow Theory supports a mildly bearish outlook on both weekly and monthly bases. Overall, the bearish trend is reinforced by the recent price action, with a significant decline in stock performance compared to the Sensex over multiple time frames.

How has been the historical performance of Poly Medicure?

Poly Medicure has shown consistent growth, with net sales increasing from 610.83 Cr in Mar'19 to 1,669.83 Cr in Mar'25, and profit after tax rising from 64.00 Cr to 333.38 Cr. The company has also strengthened its balance sheet, eliminating long-term borrowings and significantly increasing total assets and shareholder's funds.

Answer:<BR>The historical performance of Poly Medicure shows a consistent growth trajectory in net sales, with figures rising from 610.83 Cr in Mar'19 to 1,669.83 Cr in Mar'25. The total operating income has followed a similar upward trend, reaching 1,669.83 Cr in Mar'25, compared to 610.83 Cr in Mar'19. Operating profit has also increased significantly, with the operating profit (PBDIT) rising from 147.72 Cr in Mar'19 to 541.97 Cr in Mar'25. Profit before tax has shown a robust increase from 98.67 Cr in Mar'19 to 447.34 Cr in Mar'25, while profit after tax has grown from 64.00 Cr to 333.38 Cr over the same period. The company's earnings per share (EPS) have improved from 7.41 in Mar'19 to 33.41 in Mar'25, reflecting strong profitability growth. <BR><BR>In terms of balance sheet metrics, total assets have surged from 767.32 Cr in Mar'20 to 3,192.13 Cr in Mar'25, indicating significant expansion. Shareholder's funds have also increased markedly from 434.82 Cr in Mar'20 to 2,765.66 Cr in Mar'25. The company has reduced its long-term borrowings to zero by Mar'25, down from 110.57 Cr in Mar'20, showcasing a strong financial position. Cash flow from operating activities has improved, reaching 266.00 Cr in Mar'24, while the closing cash and cash equivalents increased from 4.00 Cr in Mar'20 to 12.00 Cr in Mar'24. Overall, Poly Medicure has demonstrated strong growth in revenue, profitability, and asset base over the years.<BR><BR>Breakdown:<BR>Poly Medicure's financial performance has shown remarkable growth over the years, with net sales increasing from 610.83 Cr in Mar'19 to 1,669.83 Cr in Mar'25. This growth is mirrored in total operating income, which reached 1,669.83 Cr in Mar'25, up from 610.83 Cr in Mar'19. Operating profit (PBDIT) has also seen significant growth, climbing from 147.72 Cr in Mar'19 to 541.97 Cr in Mar'25, while profit before tax rose from 98.67 Cr to 447.34 Cr in the same period. Profit after tax increased from 64.00 Cr to 333.38 Cr, and earnings per share improved from 7.41 to 33.41, indicating strong profitability. On the balance sheet, total assets surged from 767.32 Cr in Mar'20 to 3,192.13 Cr in Mar'25, with shareholder's funds rising from 434.82 Cr to 2,765.66 Cr. The company eliminated long-term borrowings, achieving a zero balance by Mar'25, and cash flow from operating activities improved to 266.00 Cr in Mar'24, with closing cash and cash equivalents increasing to 12.00 Cr. Overall, Poly Medicure has exhibited substantial growth in revenue, profit, and financial stability.

Who are the top shareholders of the Poly Medicure?

The top shareholders of Poly Medicure include promoters, with Ezekiel Global Business Solutions LLP holding 12.2%, and institutional investors, including 21 mutual fund schemes with 7.16% and 171 foreign institutional investors with 11.46%. Individual investors own 11.08%, with Quant Mutual Fund being the largest public shareholder at 3.35%.

The top shareholders of Poly Medicure include a mix of promoters, institutional investors, and individual investors. The majority shareholders are the promoters, with Ezekiel Global Business Solutions LLP holding the highest stake at 12.2%. <BR><BR>In terms of institutional holdings, 21 mutual fund schemes collectively hold 7.16%, while 171 foreign institutional investors (FIIs) account for 11.46% of the shares. The highest public shareholder is Quant Mutual Fund, specifically the Quant Small Cap Fund, which holds 3.35%. Additionally, individual investors collectively own 11.08% of the company.

Is Poly Medicure overvalued or undervalued?

As of August 29, 2022, Poly Medicure is considered very expensive and overvalued, with a PE Ratio of 66.70 and other high valuation metrics, despite a strong one-year return of 24.52%.

As of 29 August 2022, the valuation grade for Poly Medicure moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued based on its high valuation metrics. Key ratios include a PE Ratio of 66.70, an EV to EBITDA of 47.56, and a Price to Book Value of 8.17, all of which suggest that the stock is trading at a premium compared to its earnings and assets.<BR><BR>In comparison to peers, Poly Medicure's PE Ratio is notably higher than Blue Jet Health's 51.29 and Vimta Labs' 34.32, both of which are also categorized as expensive or very expensive. The PEG Ratio of 2.76 further underscores the overvaluation, especially when juxtaposed with more attractively valued companies like Raaj Medisafe, which has a PEG Ratio of 0.33. Despite a strong one-year return of 24.52% against the Sensex's 7.62%, the overall valuation metrics indicate that Poly Medicure is overvalued in the current market environment.

What is the bonus history of the Poly Medicure?

Poly Medicure has a history of issuing 1:1 bonus shares, with the most recent being on March 24, 2017. Previous bonuses were issued on July 9, 2013, and March 26, 2010, demonstrating the company's commitment to rewarding shareholders.

Poly Medicure has a history of issuing bonuses to its shareholders. The most recent bonus was a 1:1 bonus issue announced with an ex-date of March 24, 2017, and the record date was March 28, 2017. Prior to that, the company also issued a 1:1 bonus on July 9, 2013, with a record date of July 10, 2013. Additionally, there was another 1:1 bonus issued on March 26, 2010, with a record date of March 29, 2010. This consistent approach to issuing bonuses reflects the company's commitment to rewarding its shareholders.

Has Poly Medicure declared dividend?

Poly Medicure Ltd has declared a 60% dividend, amounting to ₹3 per share, with an ex-date of September 19, 2024. While the last 6 months showed a price decline of 20.81%, the company has demonstrated strong long-term growth, with total returns of 676.37% over the past 5 years.

Poly Medicure Ltd has declared a 60% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 60%<BR>- Amount per share: 3 per share<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -20.81%, with a dividend return of 0%, resulting in a total return of -20.81%.<BR><BR>Over the past year, the price return was 22.6%, the dividend return was 0.16%, leading to a total return of 22.76%.<BR><BR>In the 2-year period, the price return was 131.39%, with a dividend return of 0.52%, culminating in a total return of 131.91%.<BR><BR>For the 3-year period, the price return was 190.88%, the dividend return was 1.20%, resulting in a total return of 192.08%.<BR><BR>In the last 4 years, the price return was 123.05%, with a dividend return of 1.09%, leading to a total return of 124.14%.<BR><BR>Finally, over the past 5 years, the price return was 672.64%, the dividend return was 3.73%, resulting in a total return of 676.37%.<BR><BR>Overall, Poly Medicure has declared a significant dividend, and while the recent 6-month performance shows a decline, the longer-term returns over 1 to 5 years indicate strong growth, particularly in price returns.